.jpg)
.png)
This year promises to be an important turning point for the Pacific Lipid Association (PLA). Our goal is to reinvigorate our membership through greater opportunities to serve the PLA and National Lipid Association (NLA). This can only be done by improving member communication and engaging our membership in activities that are both personally rewarding and promote the mission and goals of the PLA/NLA.
Article By:
President-Elect, Pacific Lipid Association
Associate Professor,
Pharmacy Practice and Administration
Western University of Health Sciences,
College of Pharmacy
Pomona, CA
Treasurer, Pacific Lipid Association
Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health and Science University
Portland, OR
Diplomate, American Board of Clinical Lipidology
President, Pacific Lipid Association
Professor and Director, Heart Disease
Prevention Program
Division of Cardiology, University of California
Irvine, CA
Secretary, Pacific Lipid Association
Clinical Associate Professor/Director
Wellness Center, Kasiska Division of Health Sciences
Idaho State University
Pocatello, ID
Past President, Pacific Lipid Association
Private Practice: Endocrinology, Diabetes, Metabolism,
Internal Medicine
Medical Director and Principal Investigator
Metabolic Institute of America
Tarzana, CA
CASE STUDY
This case has unanswered questions but shows how a cardiologist and nurse practitioner who became certified lipid specialists create a team approach for their patient.
MS. TAYLOR AND DR. GREENFIELD:
Article By:
University of California-Irvine Medical Center
California Heart Associates
Fountain Valley, CA
Diplomate, American Board of Clinical Lipidology
Acute Care NP - Cardiology
MemorialCare Heart and Vascular Institute
Orange Coast Medical Center
Fountain Valley, CA
Inflammation is a dynamic process with many interconnected signaling pathways involving multiple classes of cells by which the human body responds to pathogen exposure and/or tissue damage, playing a central role in all stages of atherosclerosis. (1) Cholesterol crystals directly activate nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome and interleukin 1 beta (IL-1β) production.
Article By:
Department of Family Medicine
Oregon Health and Sciences University
Portland, OR
Diplomate, American Board of Clinical Lipidology
Along with lipid accumulation, inflammation plays a key role in the development of atherosclerosis.(1) Perhaps 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA reductase) inhibitors (statins) are effective in the prevention of atherosclerotic cardiovascular disease (ASCVD) because they significantly decrease low-density lipoprotein (LDL) particles and inflammation.
Article By:
Associate Professor, Pharmacy Practice and Administration
Western University of Health Sciences, College of Pharmacy
Pomona, CA
Atherosclerosis is widely recognized as a chronic inflammatory disorder. Therapies with anti-inflammatory effects in patients with an increased inflammatory status can reduce cardiovascular events, as the CANTOS study showed.(1) Inflammatory markers are an essential tool for evaluating a patient’s inflammatory state. The question is: which biomarker is best?
Article By:
Director, Advance Lipid Management Program
Tyler Heart Institute, Community Hospital of
Monterey Peninsula
Monterey, CA
Diplomate, American Board of Clinical Lipidology
Differentiating Biological Targets for Cardiovascular Risk Reduction from Risk Assessment Tools
Cardiovascular disease (CVD) remains the leading cause of mortality across the globe. The cornerstones of CVD prevention and treatment are accurate risk assessment — such that the intensity of preventive treatment matches the magnitude of absolute risk — and targeting biological markers that are known to mediate CV risk, respectively.
Article By:
Katz Preventive Cardiology Fellow
Division of Cardiology
Department of Medicine
Emory University School of Medicine
Atlanta, GA
Professor
Division of Cardiology
Department of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, TX
Introduction
Article By:
Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health and Science University
Portland, OR
Department of Family Medicine
Oregon Health and Science University
Portland, OR
Diplomate, American Board of Clinical Lipidology
Center for Preventive Cardiology,
Knight Cardiovascular Institute
Oregon Health and Science University
Portland, OR
Diplomate, American Board of Clinical Lipidology
The “response to retention” model of atherosclerosis holds up as the present and best narrative explanation for the initiation and propagation of atherosclerotic cardiovascular disease (ASCVD).(1) As you know, this model posits that the passage of apolipoprotein B (apoB)-containing lipoproteins (LP) triggers the initiation of the atheroma.
Article By:
Clinical Associate Professor of Medicine
University of Pennsylvania
Internal Medicine and Preventive Cardiology
University of Pennsylvania Health System
Philadelphia, PA
Diplomate, American Board of Clinical Lipidology
I am honored to have the opportunity to work with you all in promoting education, service and quality improvement efforts in clinical lipidology and preventive cardiology as this year’s President of the Pacific Lipid Association.
Article By:
President, Pacific Lipid Association Professor and Director, Heart Disease Prevention Program
Division of Cardiology, University of California
Irvine, CA
“Knowing is not enough; we must apply. Willing is not enough; we must do.” This remark by Goethe introduces readers to the rationale for the Institute of Medicine of the National Academies Committee on Standards for Developing Trustworthy Clinical Practice Guidelines: Guidelines We Can Trust 2011.
Article By:
President, National Lipid Association Director, Division of Cardiology
Advocate Lutheran General Hospital
Co-Director, Cardiology Service Line
Advocate Medical Group
Clinical Associate Professor
Loyola Stritch School of Medicine
Park Ridge, IL
Diplomate, American Board of Clinical Lipidology
Editor, LipidSpin
Clinical Associate Professor of Medicine
University of Pennsylvania
Internal Medicine and Preventive Cardiology
University of Pennsylvania Health System
Philadelphia, PA
Diplomate, American Board of Clinical Lipidology
Editor, LipidSpin
Medical Director, Lipid Clinic and Physician Advisor
Ascension Wisconsin All Saints
Racine, WI
Diplomate, American Board of Clinical Lipidology